氯吡格雷治疗非ST段抬高性急性冠脉综合征临床观察

Clinical effects of clopidogrel on patients with acute coronary syndromes without ST-segment elevation

目的:观察氯吡格雷治疗非ST段抬高急性冠脉综合征(ASS)的临床效果及安全性。方法:207例符合ACS(不稳定心绞痛/非ST抬高心肌梗塞)的患者随机分为治疗组(103例)和对照组(104例)。治疗组为在对照组治疗基础上加氯吡格雷75 mg,1次/d,口服,共1个月。对照组应用低分于肝素、阿斯匹林及调脂治疗,根据病情再给予硝酸酯类、β受体阻滞剂、钙离子拮抗剂、血管紧张素转换酶抑制剂(ACEI)类等药物。观察两组心电图改变,症状控制、主要终点事件及不良反应发生情况。结果:治疗组心电图缺血性改变有明显好转(P<0.05),1个月内心肌梗塞及心脏猝死等主要终点事件下降,无严重不良反应。结论:氯吡格雷治疗急性冠脉综合症是安全有效的。

Objective： To observe the clinical effects and safety of clopidogrel on patients with acute coronary syndrome （ACS） without ST-segment elevation. Methods： The 207 patients with ACS （unstable angina/non-ST-segment elevation myocardial infarction） were randomly divided into treatment group （n=103） and contrast group （n=104 ）. The treatment group received clopidogrel （75mg, 1/d ） for 1 month on the basis of contrast group treatment which re- ceived low molecular heparin, aspirin, statin and nitrate, β-blocker, CCB, ACEI, etc. according to the patients situation. The changes of BCG, symptoms control, primary end point events and adverse effects of drug were observed. Results： Compared with contrast group, the ECG significantly improved （P〈0.05） and the primary end point events decreased in treatment group. There was no significant adverse effect of drug in two groups. Conclusion： C]opidogrel is effective and safe for ACS patients.